Dr. Alan Moses is an independent consultant for the pharmaceutical and biotechnology sector. He serves on the Boards of two biotechnology companies and actively advises several companies in the diabetes therapy area. Dr. Moses has strong ties to Joslin. His son was admitted to the Joslin Teaching Unit with a new diagnosis of T1D in 1990. Later, from 1998 to 2004, he served as Senior Vice President and Chief Medical Officer of Joslin Diabetes Center with specific responsibility for the Joslin Clinic. 

Trained in internal medicine and endocrinology, he spent the early part of his academic career at Harvard doing bench and clinical research and clinical care. He was the Director of the Clinical Research Center at Beth Israel Hospital prior to moving to the Joslin Diabetes Center. Dr. Moses co-founded and directed the Clinical Investigator Training Program at Harvard Medical School and the HST Program at MIT. 

He joined Novo Nordisk in 2004. During his 14 years at Novo Nordisk, Dr. Moses served in multiple roles beginning as Associate Vice President of Medical Affairs in the US and rising to the position of Senior Vice President and Global Chief Medical Officer working in Copenhagen. 

Dr. Moses earned his MD from the Washington University School of Medicine in St. Louis, worked for three years at the National Institutes of Health, completed his clinical endocrine/diabetes training at Tufts New England Medical Center and studied Health Care Strategy at Harvard Business School. He retired from Novo Nordisk in June 2018.